Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.

Department of Pathology, Dongguk University College of Medicine, Kyongju, Kyongbuk, Korea.
International Journal of Experimental Pathology (Impact Factor: 2.05). 09/2002; 83(4):173-82. DOI: 10.1046/j.1365-2613.2002.00228.x
Source: PubMed

ABSTRACT We investigated the chemopreventive effect of celecoxib on 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumours and also the expression and immunolocalization of cyclooxygenase-1 (COX-1) and COX-2 in the various stages of rat mammary carcinogenesis. Rats were divided into normal control group, DMBA-control group, 500 p.p.m. celecoxib-treated group, and 1500 p.p.m. celecoxib-treated group. Both incidence and multiplicity values of tumour for rats treated with celecoxib were less than those in rats of the DMBA-control group. The level of prostaglandin E2 was higher in tumours of the DMBA-control and both celecoxib-treated groups compared to normal mammary glands of each group. In Western blot analysis, all tumours of the DMBA-control group expressed COX-1, whereas normal mammary glands showed insignificant expression. COX-2 expression was observed in 67% of the DMBA-control group and 20% of both celecoxib-treated groups and was absent in normal mammary glands. COX-1 protein was localized in the nuclear membrane and cytoplasm of epithelial tumour cells abutting on glandular lumen, stromal cells, and endothelial cells. COX-2 protein was detected in the perinuclear cytoplasm of tumour cells bordering on glandular lumen and surrounding stroma, stromal cells, and vascular smooth muscle. In the DMBA-control group, invasive carcinoma cells showed higher positive immunoreactivity of COX-2 than carcinomas in situ and atypical tumours. Tumours displayed an increased number of mast-like cells with COX-2 expression in comparison to carcinomas in situ. Our results suggest that COX-1 and COX-2 expression in tumour cells and stromal cells play an important role in the various stages of DMBA-induced rat mammary carcinogenesis. In addition, we reconfirm that celecoxib reduces the growth of DMBA-induced rat mammary tumours.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During the last few years it has been shown in several laboratories that Celecoxib (Cx), a non-steroidal anti-inflammatory agent (NSAID) normally used for pain and arthritis, mediates antitumor and antiangiogenic effects. However, the effects of this drug on a tumor cell line resistant to chemotherapeutical drugs used in cancer have not been described.
    Biological research 01/2014; 47(1):27. · 1.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclo-oxygenase-2 (COX-2) is up-regulated in malignant tumours rendering it an attractive target for cancer therapeutics. However, whether long-term antagonism maintains its initial efficacy on established tumours is unclear. 4T1 cells were injected into the mammary fat pad of BALB/c mice (n = 8). Once tumour deposits were established, animals were randomized into two equal groups to receive either a selective COX-2 inhibitor (SC-236) or a drug vehicle. Further animals similarly treated (n = 7) were studied in diuresis cages allowing urine capture and analysis by mass spectrometry to determine Prostaglandin F-1 levels (PGF-1). In addition, both wild-type receiving SC-236 and COX-2 knockout mice receiving either SC 236 or vehicle were subjected to the same studies to determine whether tumour-derived or host-derived (stromal) COX-2 was the critical element. Finally, BALB/c mice with 4T1 tumours (n = 7) were treated with a combination of COX-2 and lipoxygenase (LOX) inhibition to attenuate this escape phenomenon. While selective COX-2 inhibition initially retarded tumour growth, a rapid increase in tumour growth rate occurred later (day 9). This escape phenomenon correlated with an increase in urinary PGF-1 levels. An identical trend was also observed whether COX-2 knockout mice received SC-236 or not, suggesting that this effect is due to increased tumour-derived COX-2 production rather than recovery of host COX-2 functional capacity. Finally, dual inhibition of COX and LOX pathways attenuated this escape process. The anti-neoplastic effects of selective COX-2 inhibition may not be sustained as tumours demonstrate an escape capacity. However, this phenomenon maybe attenuated by a combination of COX/LOX inhibitors.
    Irish Journal of Medical Science 05/2009; 178(2):201-8. · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: At present, the majority of established treatments for breast cancer are based on clinical manifestations, some fundamental of molecular and cellular biology of cancer. In recent times, the therapy is moving towards personalized medicines. Nevertheless, both the methodologies have own demerits. In the present study, we proposed a novel idea of targeted therapy with twin pharmacological potential by a peptide pACC1. The peptide was formulated with chitosan and evaluated with DMBA induced mammary carcinoma. Results suggest that the peptide holds great control on tumor cell multiplication, fatty acid synthesis and lactate levels. In addition, peptide also brings normal metabolic signs in glycolytic and glycogenic pathways. Histological studies confirm the dual pharmacological actions. Further, it is also proven that the peptide controls membrane receptor levels of HER2 and EGFR. In conclusion, that the peptide pACC1 could be employed as greater therapeutic adjuvant with currently established drugs without considering the stage of the cancer.
    Biomedecine [?] Pharmacotherapy 07/2014; · 2.11 Impact Factor


Available from